Over the past week, UnitedHealth shares climbed 7.3% as retail investor sentiment on Reddit and X swung sharply from deeply bearish to neutral. Sentiment scores moved from an 18 reading in November to a peak of 82 in December before settling at 42 today. This shift reflects cooling hostility on r/WallStreetBets and growing interest from options traders, highlighted by a late-January post describing a deep in-the-money call position that recovered after a drop to $310. The stock now trades near its 50-day and 200-day moving averages of $331 and $338 respectively, bolstered by Berkshire Hathaway’s 5 million-share stake and sustained LEAPS discussions among institutional and retail participants.

The Federal Trade Commission has stayed its administrative case against UnitedHealth’s pharmacy benefit manager unit for 14 days, pushing back the evidentiary hearing to July 1 and rescheduling oral arguments to February 5. The original complaint, filed in September, accused PBMs of anti-competitive practices that inflated insulin list prices and imposed massive markups on specialty generics. The suspension applies to all respondents, suggesting settlement talks may be underway. This pause follows a January interim report highlighting markups of hundreds to thousands of percent on critical therapies and intensifying political pressure on PBMs’ rebate structures.

UnitedHealth’s CEO testified before Congress that rising hospital and drug prices—rather than insurers—drive U.S. health spending. He pledged to eliminate and rebate profits on Affordable Care Act exchange coverage this year, though details remain pending. He also noted the company negotiated nearly $300 billion in provider discounts and saved $35 billion through fraud-and-waste reduction in the last year. In addition, a new Rural Payment Acceleration Pilot aims to cut Medicare Advantage payment collection times for rural hospitals from under 30 days to under 15 days, targeting facilities in Oklahoma, Idaho, Minnesota and Missouri.